17 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 35508605 | The importance of CYP2C19 genotype in tacrolimus dose optimization when concomitant with voriconazole in heart transplant recipients. | 2022 May 4 | 6 |
2 | 32308538 | Tacrolimus Concentration after Letermovir Initiation in Hematopoietic Stem Cell Transplantation Recipients Receiving Voriconazole: A Retrospective, Observational Study. | 2020 | 1 |
3 | 31096684 | Impact of CYP3A5, POR, and CYP2C19 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplantation. | 2019 May 15 | 3 |
4 | 31244435 | Association of Genetic Variants in CYP3A4, CYP3A5, CYP2C8, and CYP2C19 with Tacrolimus Pharmacokinetics in Renal Transplant Recipients. | 2019 | 1 |
5 | 26239045 | Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole. | 2016 Apr | 3 |
6 | 27191765 | Dose regimens for Chinese adult liver transplant recipients according to the genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in recipients and donors. | 2016 Aug | 1 |
7 | 23175667 | Increased hospital stay and allograft dysfunction in renal transplant recipients with Cyp2c19 AA variant in SNP rs4244285. | 2013 Feb | 6 |
8 | 21883747 | A clinically significant interaction between tacrolimus and multiple proton pump inhibitors in a kidney transplant recipient. | 2012 Sep | 2 |
9 | 21366650 | Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. | 2011 Apr | 1 |
10 | 21802143 | Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations. | 2011 Aug | 2 |
11 | 23213600 | Fatal lactic acidosis in a kidney transplant recipient on combination antiretroviral therapy after initiation of tacrolimus therapy. | 2011 | 1 |
12 | 20596503 | Investigation of clinical interaction between omeprazole and tacrolimus in CYP3A5 non-expressors, renal transplant recipients. | 2010 Jun 24 | 1 |
13 | 19139162 | Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. | 2009 Apr | 3 |
14 | 17377957 | Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. | 2007 May | 4 |
15 | 15010519 | Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism. | 2004 May | 3 |
16 | 15285851 | Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. | 2004 Aug | 4 |
17 | 12431607 | Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation. | 2002 Nov | 1 |